KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Financing Activities (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Cash from Financing Activities for 17 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 112.6% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$283.2 million, a 29.43% decrease, with the full-year FY2025 number at -$283.2 million, down 29.43% from a year prior.
  • Cash from Financing Activities was $3.3 million for Q4 2025 at Bio-Rad Laboratories, up from -$52.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $1.2 billion in Q1 2022 to a low of -$202.7 million in Q2 2023.
  • A 5-year average of -$496263.2 and a median of -$47.3 million in 2021 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 2613.98% in 2022; the steepest drop was 4334.76% in 2022.
  • Bio-Rad Laboratories' Cash from Financing Activities stood at $4.6 million in 2021, then crashed by 1968.28% to -$86.6 million in 2022, then plummeted by 131.62% to -$200.6 million in 2023, then skyrocketed by 86.94% to -$26.2 million in 2024, then skyrocketed by 112.6% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Cash from Financing Activities are $3.3 million (Q4 2025), -$52.5 million (Q3 2025), and -$136.3 million (Q2 2025).